lobbying_activities: 632868

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
632868	df777223-d31e-424a-ae90-fee6eaf66ddf	Q2	AMYLIN PHARMACEUTICALS	308536	AMYLIN PHARMACEUTICALS	2008	second_quarter	PHA	H.R. 1038, Access to Life-Saving Medicine Act, follow-on biologics H.R. 1561, Enhancing Drug Safety and Innovation Act of 2007, drug safety provisions H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics S. 1505, Affordable Biologics for Consumers Act, follow-on biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S. 2029, Physician Payments Sunshine Act of 2007 S. 596 Safe Internet Pharmacy Act of 2007, clinical trials, drug safety provisions S. 623, Access to Life-Saving Medicine Act, follow-on biologics Drug Importation H.R., Pathway for Biosimilars Act H.R. 5839, Safeguarding America's Pharmaceuticals Act of 2008	Centers For Medicare and Medicaid Services (CMS),Commerce, Dept of (DOC),Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE		495000	0	0	2008-07-17T10:47:56-04:00